ArticleBMC primary care2026
Prevalence of ECG-detected and previously unrecognized atrial fibrillation among older adults attending a family health center: a single-center cross-sectional screening study.
Article in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is an important and often unrecognized cause of ischemic stroke in older adults. The primary objective of this study was to determine the prevalence of AF detected by a single 12-lead ECG among adults aged ≥ 65 years attending primary care. Secondary objectives were the proportion previously unrecognized, thromboembolic risk and anticoagulant use, and associated characteristics.
methodsThis single-center cross-sectional study enrolled consecutive consenting adults aged ≥ 65 years attending a family health center in Istanbul, Türkiye (May 2021-May 2022). Of 359 assessed, 2 with pacemakers were excluded, leaving 357. AF on the screening 12-lead ECG was diagnosed by the investigator and confirmed by a cardiologist; AF was classified as previously known when a prior diagnosis was reported and as previously unrecognized otherwise. The study-period anticoagulation threshold was defined as CHA₂DS₂-VASc ≥ 2 in men and ≥ 3 in women. Prevalences are reported with Wilson 95% confidence intervals (CIs); associations were examined with chi-square or exact tests and exploratory Firth penalized logistic regression.
resultsAF was detected on the screening ECG in 42 participants (11.8%; 95% CI 8.8-15.5), with similar prevalence by sex. Prevalence differed across age groups (P=.034), with the highest estimate among participants aged ≥ 80 years (26.3%; 95% CI 15.0-42.0). Twenty-two of the 42 ECG-detected AF cases were previously unrecognized (52.4%; 6.2% of all screened participants, 95% CI 4.1-9.2). In an exploratory adjusted model, heart failure (aOR 5.71; 95% CI 1.81-18.00) and chronic lung disease (aOR 2.53; 95% CI 1.24-5.19) were associated with ECG-detected AF, whereas the age estimate was attenuated after adjustment (aOR 1.69 per decade; 95% CI 0.98-2.90). The mean CHA₂DS₂-VASc score was 3.64 ± 1.53, and 37 participants with AF (88.1%) met the study-period anticoagulation threshold. Twenty were not receiving anticoagulation at screening, including 18 with previously unrecognized AF; this group represented 5.6% of all screened participants (95% CI 3.7-8.5).
conclusionA single screening ECG identified previously unrecognized AF, including individuals who would meet a guideline-based threshold for consideration of anticoagulation after clinical evaluation. These findings describe the potential yield of opportunistic AF detection in this primary-care setting but do not establish population-level screening effectiveness or clinical benefit.
Indexed as
Identifiers
42920118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.